|

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

RECRUITINGPhase 2Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Actively Recruiting
PhasePhase 2
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Started2025-02-25
Est. completion2027-06
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06376669

Summary

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age ≥ 18 years
2. Biopsy proven renal cell carcinoma.
3. No clinical or radiographic evidence of metastatic disease.
4. Not a candidate for surgical treatment or local ablative procedures.
5. Subjects are able to undergo either an MRI or administration of contrast agent for CT.

Exclusion Criteria:

1. Prior history of radiation treatment with overlapping fields.
2. Patients with proven metastatic disease.
3. Female subjects who are pregnant or planning to become pregnant during the treatment.

Conditions2

CancerRenal Cell Carcinoma

Locations1 site

Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016
Sherif Shaaban202-919-2523sshaaba1@jhmi.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.